Mode
Text Size
Log in / Sign up

Retrospective review of methylprednisolone response in children with TBX4-associated pulmonary hypertension and interstitial lung diseasePulsed steroids may help children with TBX4-linked lung disease and pulmonary hypertension

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider potential benefits of methylprednisolone in TBX4-associated PH based on retrospective data; prospective evaluation is warranted.

This publication is a review of a retrospective study involving 21 children aged ≤18 years with TBX4-associated pulmonary hypertension and interstitial lung disease. The setting was a national centre evaluating pulsed intravenous methylprednisolone against untreated children. Follow-up duration was not reported. Primary outcomes included response using ChILD-EU categories. Secondary outcomes included respiratory severity score, functional class, echocardiographic measures, and NT-proBNP. 7/9 patients demonstrated clear or best response to corticosteroids. Respiratory severity scores improved in 6/9 patients (p=0.02). all on respiratory support achieved partial or complete weaning.

Functional class improved in all with FC III/IV at baseline (p=0.02). Right ventricular function measured by TAPSE z-score improved by +1.65 (p=0.04). NT-proBNP levels normalised. Early improvement was not observed in untreated children. The study compares treated subjects to untreated children regarding these specific clinical metrics. Authors note this is a retrospective study and evidence for ILD-directed therapy in this group is lacking. No significant adverse effects were observed. Serious adverse events and discontinuations were not reported. Further prospective evaluation is warranted. Corticosteroids were associated with meaningful improvements, but causality is not established. Do not overstate association versus causation or surrogate versus clinical outcomes. Certainty of evidence was not reported. Funding or conflicts were not reported.

Researchers reviewed records of 21 children aged 18 or younger who had TBX4-associated pulmonary hypertension at a national center. Nineteen of these children received pulsed intravenous methylprednisolone, while the records of two untreated children were also examined for comparison.

The children who received the steroid treatment showed significant improvement. About 78% had a clear or best response, and those with severe breathing issues or lower functional class improved. Measures of heart function and a marker of heart strain also normalized or improved in the treated group. Children on breathing support were able to wean off it.

In contrast, untreated children did not show early improvement. No significant adverse effects were observed in the treated group, and the medication was generally well tolerated. Despite these positive findings, the study design limits what can be concluded. The evidence for using this therapy specifically for interstitial lung disease in this group is currently lacking. A prospective evaluation is warranted before this approach becomes standard practice.

What this means for you:
Pulsed steroids were associated with improvement in a small group of children, but larger studies are needed.

Study Details

EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Background: TBX4 variants are a recognised cause of paediatric pulmonary hypertension (PH), often associated with interstitial lung disease (ILD). Evidence for ILD-directed therapy in this group is lacking. Methods: We conducted a retrospective study of children ([≤]18 years) with TBX4-associated PH at a national centre (2001-2025). ILD was defined using ChILD-EU criteria. Patients treated with pulsed intravenous methylprednisolone were assessed for response using ChILD-EU categories. Secondary outcomes included respiratory severity score (RSS), functional class (FC), echocardiographic measures, and NT-proBNP. Results: Of 21 children, 11 (52%) had ILD; 9 received corticosteroids. Median age at treatment was 0.8 years. A clear or best response occurred in 7/9 (78%). RSS improved in 6/9 (p=0.02), with all children on respiratory support showing partial or complete weaning. Functional class improved in all with FC III/IV at baseline (p=0.02). Right ventricular function improved (TAPSE z-score +1.65, p=0.04), and elevated NT-proBNP normalised. Key clinical milestones included ECMO weaning, transplant delisting, and discontinuation of prostacyclin therapy. No significant adverse effects were observed. Untreated children showed no early improvement. Conclusions: Corticosteroids were associated with meaningful improvements in respiratory and PH outcomes in TBX4-associated PH with ILD. Prospective evaluation is warranted.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.